(Total Views: 264)
Posted On: 07/29/2019 9:29:40 AM
Post# of 154062
Merck's Keytruda shows positive effect in late-stage TNBC study;
Jul. 29, 2019 8:26 AM ET|About: Merck & Co., Inc. (MRK)|By: Douglas W. House, SA News Editor
Merck (NYSE:MRK) perks up 1% premarket on light volume in response to positive results from a Phase 3 clinical trial, KEYNOTE-522, evaluating Keytruda (pembrolizumab), combined with chemo, compared to placebo + chemo as neoadjuvant therapy followed by Keytruda compared to placebo as adjuvant therapy in patients with triple-negative breast cancer (TNBC).
The dual primary endpoints are pathological complete response (pCR) rate up to week 30 and event-free survival up to ~eight years. The estimated completion date is September 2025.
Interim data showed a statistically significant improvement in pCR in the Keytruda cohort compared to chemo alone regardless of PD-L1 status. The study will continue unchanged to assess the survival endpoint.
Good that we have our CTC levels surrogate endpoint!
Jul. 29, 2019 8:26 AM ET|About: Merck & Co., Inc. (MRK)|By: Douglas W. House, SA News Editor
Merck (NYSE:MRK) perks up 1% premarket on light volume in response to positive results from a Phase 3 clinical trial, KEYNOTE-522, evaluating Keytruda (pembrolizumab), combined with chemo, compared to placebo + chemo as neoadjuvant therapy followed by Keytruda compared to placebo as adjuvant therapy in patients with triple-negative breast cancer (TNBC).
The dual primary endpoints are pathological complete response (pCR) rate up to week 30 and event-free survival up to ~eight years. The estimated completion date is September 2025.
Interim data showed a statistically significant improvement in pCR in the Keytruda cohort compared to chemo alone regardless of PD-L1 status. The study will continue unchanged to assess the survival endpoint.
Good that we have our CTC levels surrogate endpoint!
(0)
(0)
